Delving into the Latest Updates on Harbin Pharmaceutical Group Bioengineering Co. Ltd. with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Immune System Diseases

Digestive System Disorders

Biosimilar

Colony-stimulating factors

Interferons

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	3
Infectious Diseases	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Biosimilar	3
Colony-stimulating factors	2
Interferons	1

Top 5 Target	Count

IFNAR(Interferon alpha/beta receptor)	1
EPO receptor(Erythropoietin receptor)	1
CSF-2R(Granulocyte-macrophage colony-stimulating factor receptor)	1

To improve the oral bioavailability of nanocrystalline drug preparations, the cationic 12-3-12 quaternary ammonium surfactant gemini was introduced into nanocrystals as a novel gastrointestinal bioadhesive material. Coenzyme Q10 (CoQ10), a typical Biopharmaceutics Classification System (BCS) class II drug, was used as a model drug. The 12-3-12 gemini surfactant was added to the preparation at a low concentration and imbued the particles with abundant positive charges. In vitro and in vivo gastrointestinal adhesion tests confirmed that the gemini-modified nanocrystals were prone to adhere to the upper gastrointestinal tract (GIT), thereby prolonging retention time in the GIT and enhancing absorption. In the distribution study in rats, the use of nanocrystals modified with gemini led to greater drug distribution to the heart and the liver than that achieved with the naked nanocrystals. A pharmacokinetic study in beagle dogs showed that the gemini-modified CoQ10 nanocrystals improved the oral bioavailability of CoQ10 in a dose-dependent manner, and the smaller size produced a much better effect with the same gemini modification. These results demonstrate that the cationic surfactant gemini is a promising oral bioadhesive material with applications in nanoscale drug delivery systems.

Zhongguo Yaofang

Formulation of alprostadil and the research progress

Author: Wang, Xuegong ; Zhou, Xinrong ; Xiao, Minghui ; Tang, Xiaobo

A review with 21 references to introduce the formulation of alprostadil and the research progress.The present formulation of alprostadil such as injection powder, injection emulsion, urethral suppository, and ointment, and novel formulation such as injection liposome, freeze-drying powder, cyclodextrin inclusion freeze-drying powder, freeze-drying emulsion, micelle for injection, nasal powder, and buccal tablets, are discussed.

RSC AdvancesQ3 · CHEMISTRY

Continuous hydrogen production from glucose/xylose by an anaerobic sequential batch reactor to maximize the energy recovery efficiency

Q3 · CHEMISTRY

ArticleOA

Author: Guo, Wan-Qian ; Ren, Nan-Qi ; Ren, Hong-Yu ; Zhao, Lei ; Cao, Guang-Li ; Wu, Jie-Ting ; Guo, Xu-Chao ; Wang, Ai-Jie

Fermentation of both glucose and xylose is essential to realize efficient bioconversion of renewable and abundant lignocellulosic biomass to hydrogen.

100 Deals associated with Harbin Pharmaceutical Group Bioengineering Co. Ltd.

Login to view more data

100 Translational Medicine associated with Harbin Pharmaceutical Group Bioengineering Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human granulocyte/macrophage colony-stimulating factor(Harbin Pharmaceutical Group Co., Ltd.) ( CSF-2R )	Myelodysplastic Syndromes More	Approved
Recombinant human erythropoietin (CHO Cell), Harbin Pharmaceutical Group Bioengineering(Harbin Pharmaceutical Group Co., Ltd.) ( EPO receptor )	Anemia More	Approved
Recombinant human interferon alfa-2b(Harbin Pharmaceutical Group Co., Ltd.) ( IFNAR )	Condylomata Acuminata More	Approved